256 related articles for article (PubMed ID: 24729449)
1. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
2. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858
[TBL] [Abstract][Full Text] [Related]
4. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression.
Imada K; Shiota M; Kohashi K; Kuroiwa K; Song Y; Sugimoto M; Naito S; Oda Y
Clin Cancer Res; 2013 Sep; 19(17):4638-50. PubMed ID: 23838318
[TBL] [Abstract][Full Text] [Related]
5. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
[TBL] [Abstract][Full Text] [Related]
6. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer.
Shiota M; Zoubeidi A; Kumano M; Beraldi E; Naito S; Nelson CC; Sorensen PH; Gleave ME
Mol Cancer Res; 2011 Dec; 9(12):1755-66. PubMed ID: 21987172
[TBL] [Abstract][Full Text] [Related]
7. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
[TBL] [Abstract][Full Text] [Related]
8. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
9. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer.
Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK
Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous Targeting of RSK and AKT Efficiently Inhibits YB-1-Mediated Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks in Breast Cancer Cells.
Lettau K; Zips D; Toulany M
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):567-580. PubMed ID: 32931865
[TBL] [Abstract][Full Text] [Related]
11. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Signal-regulated Kinase (ERK)-dependent Phosphorylation of Y-Box-binding Protein 1 (YB-1) Enhances Gene Expression in Granulosa Cells in Response to Follicle-stimulating Hormone (FSH).
Donaubauer EM; Hunzicker-Dunn ME
J Biol Chem; 2016 Jun; 291(23):12145-60. PubMed ID: 27080258
[TBL] [Abstract][Full Text] [Related]
13. CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling.
Kato T; Fujita Y; Nakane K; Mizutani K; Terazawa R; Ehara H; Kanimoto Y; Kojima T; Nozawa Y; Deguchi T; Ito M
Cytokine; 2013 Oct; 64(1):251-7. PubMed ID: 23876400
[TBL] [Abstract][Full Text] [Related]
14. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.
Fujita Y; Kojima T; Kawakami K; Mizutani K; Kato T; Deguchi T; Ito M
Prostate; 2015 Oct; 75(14):1568-78. PubMed ID: 26074357
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
[TBL] [Abstract][Full Text] [Related]
16. Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models.
Sechi M; Lall RK; Afolabi SO; Singh A; Joshi DC; Chiu SY; Mukhtar H; Syed DN
Sci Rep; 2018 Oct; 8(1):15726. PubMed ID: 30356079
[TBL] [Abstract][Full Text] [Related]
17. The roles of Y-box-binding protein (YB)-1 and C-X-C motif chemokine ligand 14 (CXCL14) in the progression of prostate cancer via extracellular-signal-regulated kinase (ERK) signaling.
Wang C; Zhao N; Sato F; Tanimoto K; Okada H; Liu Y; Bhawal UK
Bioengineered; 2021 Dec; 12(2):9128-9139. PubMed ID: 34696665
[TBL] [Abstract][Full Text] [Related]
18. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
Kang Y; Hu W; Ivan C; Dalton HJ; Miyake T; Pecot CV; Zand B; Liu T; Huang J; Jennings NB; Rupaimoole R; Taylor M; Pradeep S; Wu SY; Lu C; Wen Y; Huang J; Liu J; Sood AK
J Natl Cancer Inst; 2013 Oct; 105(19):1485-95. PubMed ID: 24062525
[TBL] [Abstract][Full Text] [Related]
19. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
[TBL] [Abstract][Full Text] [Related]
20. An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer.
Ushijima M; Shiota M; Matsumoto T; Kashiwagi E; Inokuchi J; Eto M
Cancer Sci; 2022 May; 113(5):1731-1738. PubMed ID: 35118769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
